BioNTech (BNTX) Stock Drops 8% After Colorectal Cancer mRNA Vaccine Trial Terminated
TLDR
- BioNTech stock fell around 8% Friday after it ended a Phase 2 trial for mRNA cancer vaccine autogene cevumeran in colorectal cancer
- An independent safety board recommended stopping the trial early, citing futility and an imbalance in survival outcomes between treatment groups
- This is the second trial failure for autogene cevumeran in 2026, following a bladder cancer halt in March
- The setback contrasts sharply with last week’s mRNA rally, when Moderna and Merck reported a successful Phase 3 melanoma vaccine trial
- BioNTech still holds €16.6 billion in cash, and its pancreatic cancer trial remains ongoing
BioNTech stock dropped roughly 8% on Friday after the company and Genentech terminated a Phase 2 clinical trial for their mRNA cancer vaccine in colorectal cancer. The stock was trading around $104 before the announcement.
The trial was evaluating autogene cevumeran as an add-on treatment for patients with high-risk Stage II or Stage III colorectal cancer following surgery.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
